Senzime AB (SEZI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-23.03 Million ≈ $-2.48 Million USD) by net assets (Skr283.50 Million ≈ $30.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SEZI equity financing ratio to measure how much of total assets are equity-financed.
Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Senzime AB (SEZI) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Senzime AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kredyt Inkaso SA
WAR:KRI
|
0.105x |
|
3P Learning Ltd
AU:3PL
|
0.087x |
|
PUBLIC POLICY HO.COM 144A
F:PD7
|
N/A |
|
Cryomax Cooling System Corp
TW:1587
|
0.051x |
|
WeGrow AG
DU:ZN2
|
N/A |
|
Korea Computer & Systems Inc
KQ:115500
|
0.074x |
|
Kronox Lab Sciences Ltd
NSE:KRONOX
|
0.090x |
|
Nurminen Logistics Oyj
HE:NLG1V
|
0.125x |
Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)
The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Senzime AB (SEZI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr304.46 Million ≈ $32.76 Million |
Skr-109.10 Million ≈ $-11.74 Million |
-0.358x | -16.98% |
| 2024-12-31 | Skr345.86 Million ≈ $37.22 Million |
Skr-105.94 Million ≈ $-11.40 Million |
-0.306x | -0.97% |
| 2023-12-31 | Skr375.48 Million ≈ $40.41 Million |
Skr-113.91 Million ≈ $-12.26 Million |
-0.303x | +41.91% |
| 2022-12-31 | Skr261.90 Million ≈ $28.18 Million |
Skr-136.78 Million ≈ $-14.72 Million |
-0.522x | +3.31% |
| 2021-12-31 | Skr150.58 Million ≈ $16.20 Million |
Skr-81.33 Million ≈ $-8.75 Million |
-0.540x | -225.94% |
| 2020-12-31 | Skr231.35 Million ≈ $24.90 Million |
Skr-38.34 Million ≈ $-4.13 Million |
-0.166x | +0.04% |
| 2019-12-31 | Skr163.69 Million ≈ $17.62 Million |
Skr-27.14 Million ≈ $-2.92 Million |
-0.166x | -56.49% |
| 2018-12-31 | Skr167.41 Million ≈ $18.02 Million |
Skr-17.73 Million ≈ $-1.91 Million |
-0.106x | -21.04% |
| 2017-12-31 | Skr140.46 Million ≈ $15.12 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.088x | -15.36% |
| 2016-12-31 | Skr131.87 Million ≈ $14.19 Million |
Skr-10.00 Million ≈ $-1.08 Million |
-0.076x | +45.81% |
| 2015-12-31 | Skr45.81 Million ≈ $4.93 Million |
Skr-6.41 Million ≈ $-690.18K |
-0.140x | -60.40% |
| 2014-12-31 | Skr44.08 Million ≈ $4.74 Million |
Skr-3.85 Million ≈ $-414.05K |
-0.087x | +39.78% |
| 2013-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-5.43 Million ≈ $-584.31K |
-0.145x | +23.55% |
| 2012-12-31 | Skr31.99 Million ≈ $3.44 Million |
Skr-6.06 Million ≈ $-652.57K |
-0.190x | -170.80% |
| 2011-12-31 | Skr27.87 Million ≈ $3.00 Million |
Skr-1.95 Million ≈ $-209.94K |
-0.070x | +27.67% |
| 2010-12-31 | Skr21.90 Million ≈ $2.36 Million |
Skr-2.12 Million ≈ $-228.10K |
-0.097x | -0.30% |
| 2009-12-31 | Skr16.61 Million ≈ $1.79 Million |
Skr-1.60 Million ≈ $-172.54K |
-0.096x | -664.63% |
| 2006-12-31 | Skr7.55 Million ≈ $812.29K |
Skr129.00K ≈ $13.88K |
0.017x | -- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more